Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays.

Rachel NiceNeil Chanchlani Harry D Green Claire M Bewshea Tariq Ahmad James R Goodhand Timothy James McDonaldMandy H PerryNicholas Alexander Kennedy

Published in: Alimentary pharmacology & therapeutics (2020)

Laboratories should derive antibody positivity thresholds for assays they use. For adalimumab, low-concentration anti-drug antibodies were associated with lower drug levels and treatment failure.

Keyphrases

rheumatoid arthritis
ulcerative colitis
high throughput
juvenile idiopathic arthritis
adverse drug
drug induced
combination therapy
disease activity
replacement therapy